

## Information about proposed Board of Directors Annual General Meeting 2015

---

### ***Proposal for re-election of the current members of the board of directors:***

#### **Annette Clancy**

Born 1954.

Board member since 2014

BSc Hons Pharmacology, from Bath University UK.

*Other assignments:* Chair and Board member in Genable Technologies. Board member of Lysogene. She is also Senior European Advisor to the Biopharmaceutical Team in Frazier Healthcare Ventures, where she provides strategic advice regarding investments. More than 30 years' experience from the pharmaceutical /biotechnology industry in a variety of functions (R&D, Marketing, Global Business Development) both in the US and the UK.

*Previous assignments:* Head of Transactions and Alliance Management at GlaxoSmithKline (GSK). Board member of Silence Therapeutics plc. and Clavis Pharma in Norway.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

#### **Matthew Gantz**

Born 1965.

Board member since 2012.

BA Princeton University and MBA from Harvard Business School.

*Other assignments:* US Executive Vice President of BTG, an international specialist healthcare company.

*Previous assignments:* Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for Patho Genesis Europe. Prior to Chiron/PathoGenesis, a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Adine Grate Axén**

Born 1961.

Board member since 2010.

M.Sc. from Stockholm School of Economics, Harvard AMP.

*Other assignments:* Board member of BSKyB Ltd, Sampo OY, HI3GS Holding AB, 3GIS Infrastructure Services AB, HI3G Denmark ApS, Madrague AB and Swedavia AB. Chairman of Nasdaq OMX Stockholm's Listing Committee and Vice Chairman of Sjunde AP-fonden.

*Previous assignments:* Member of the Advisory Committee for Sale of State-owned Companies. Board member of Gambro AB, OMX AB, several senior positions and Board assignments at Investor AB and member of the management group. Board member of Acne Studios Holding AB, Evry AS and Carnegie Investment Bank AB.

*Aktier:* 32 000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Bo Jesper Hansen**

Born 1958.

Chairman and Board member since 2010.

M.D. with a Ph.D. from Copenhagen University.

*Other assignments:* Board member of HyperionTherapeutics Inc., GenSpera Inc., Newron Pharmaceuticals SpA, Orphazyme ApS, Karolinska Development AB, and Ablynx NV.

*Previous assignments:* Various positions in Swedish Orphan International AB since 1993 including CEO from 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research.

*Shares:* 8,893,846

Dependent in relation to the company and its management but independent in relation to the company's principal shareholders.

**Lennart Johansson**

Born 1955.

Board member since 2010.

M.Sc. from Stockholm School of Economics.

*Other assignments:* Member of the management team and Head of Financial Investments at Investor AB. Board member of HI3G.

*Previous assignments:* CEO of b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB, Gambro Holding AB and Mölnlycke Health Care.

*Shares:* 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Helena Saxon**

Born 1970.

Board member since 2011.

M.Sc. from Stockholm School of Economics.

*Other assignments:* CFO at Investor AB, Board member of Aleris and Mölnlycke Health Care.

*Previous assignments:* CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs.

*Shares:* 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Hans GCP Schikan**

Born 1958.

Board member since 2011.

Pharm.D, Utrecht University.

*Other assignments:* CEO of Prosensa, The Netherlands. Board member of Core Team Dutch Top Sector Life Sciences & Health. Member of the Biotechnology Industry Organization's Emerging Companies Section Governing Board. Member of the Advisory Board of BioScience Park Leiden.

*Previous appointments:* Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme. Board member Top Institute Pharma.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Hans Wigzell**

Born 1938.

Board member since 2005.

M.D,D.Sc., Professor of Immunology.

*Other assignments:* Chairman of Rhenman & Partners Asset Management AB. Board member of Karolinska Development, RaySearch Laboratories AB (publ), Valneva SE(publ), Sarepta Therapeutics Inc (publ) and AB Wigzellproduktion. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences.

*Previous assignments:* Vice Chancellor of Karolinska Institutet. Board member of NeoDynamics AB, PROBI AB and Diamyd Medical AB.

*Shares:* 200,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.